High Net Worth Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

High Net Worth Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-302	Closed	-$215K	–	221
2024 Q4	$215K	Hold	302	–	–	0.06%	208
2024 Q3	$317K	Hold	302	–	–	0.09%	167
2024 Q2	$317K	Hold	302	–	–	0.1%	152
2024 Q1	$291K	Hold	302	–	–	0.09%	166
2023 Q4	$265K	Hold	302	–	–	0.1%	159
2023 Q3	$249K	Hold	302	–	–	0.1%	158
2023 Q2	$217K	Buy	302 +26	+9%	+$20K	0.08%	181
2023 Q1	$227K	Buy	276 +26	+10%	+$19.6K	0.09%	168
2022 Q4	$180K	Hold	250	–	–	0.07%	195
2022 Q3	$172K	Hold	250	–	–	0.07%	194
2022 Q2	$148K	Hold	250	–	–	0.06%	209
2022 Q1	$175K	Hold	250	–	–	0.06%	200
2021 Q4	$158K	Buy	+250	New	+$154K	0.06%	208

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

High Net Worth Advisory Group's REGN Position: Q1 2025 in Review

High Net Worth Advisory Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 302 shares — an estimated $215K sold.

High Net Worth Advisory Group first reported a position in REGN in Q4 2021 and held it in 13 quarters. The position peaked at $317K in Q3 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

High Net Worth Advisory Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
High Net Worth Advisory Group sold 302 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $215K.
High Net Worth Advisory Group first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 13 quarters.
High Net Worth Advisory Group's Regeneron Pharmaceuticals position peaked at $317K in Q3 2024.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on High Net Worth Advisory Group's 13F filing for Q1 2025, filed 9 Apr 2025.